Literature DB >> 3041111

The multicomponent analysis of estrogens in urine by ion exchange chromatography and GC-MS--I. Quantitation of estrogens after initial hydrolysis of conjugates.

T Fotsis, H Adlercreutz.   

Abstract

A method for the multicomponent analysis of estrogens in urine after initial hydrolysis of the conjugates is described. Following protection of the carbonyl functions by ethoximation, estrogen conjugates were extracted on Sep-Pak C18 cartridges and purified on the acetate form of DEAE-Sephadex. The samples were subsequently hydrolysed by Helix pomatia juice and the hydrolysate was purified on the acetate form of QAE-Sephadex. Estrogens with vicinal cis-hydroxyls and diphenolic compounds were fractionated on the borate and bicarbonate form of QAE-Sephadex, respectively. Neutral steroids were removed by the free base form of DEAE-Sephadex after which estrogens were separated into two groups using Lipidex 5000 in a straight phase system. Following trimethylsilyl ether derivatization estrogens were analysed by selected ion monitoring (SIM). The method allows the quantitation of all the important estrogen metabolites including catechol estrogens. It is precise, accurate and sensitive permitting the quantitation of estrogens in urine of males and non-pregnant females.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3041111     DOI: 10.1016/0022-4731(87)90379-7

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  9 in total

1.  Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer.

Authors:  P E Lønning; S I Helle; D C Johannessen; D Ekse; H Adlercreutz
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Genistein, a dietary-derived inhibitor of in vitro angiogenesis.

Authors:  T Fotsis; M Pepper; H Adlercreutz; G Fleischmann; T Hase; R Montesano; L Schweigerer
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

3.  Fat/fiber intakes and sex hormones in healthy premenopausal women in USA.

Authors:  Mylène Aubertin-Leheudre; Sherwood Gorbach; Margo Woods; Johanna T Dwyer; Barry Goldin; Herman Adlercreutz
Journal:  J Steroid Biochem Mol Biol       Date:  2008-08-09       Impact factor: 4.292

4.  Neonatal exposure to coumestrol, a phytoestrogen, does not alter spermatogenic potential in rats.

Authors:  C A Awoniyi; D Roberts; V Chandrashekar; D N Veeramachaneni; B S Hurst; K E Tucker; W D Schlaff
Journal:  Endocrine       Date:  1997-12       Impact factor: 3.633

Review 5.  Aromatase inhibitor development for treatment of breast cancer.

Authors:  S Masamura; H Adlercreutz; H Harvey; A Lipton; L M Demers; R J Santen; S J Santner
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

6.  Determination of 17 β-Estradiol in Rabbit Plasma by Gas Chromatography with Flame Ionization Detection.

Authors:  B Yilmaz; Y Kadioglu
Journal:  Indian J Pharm Sci       Date:  2012-05       Impact factor: 0.975

7.  Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16alpha-hydroxyestrone in urine.

Authors:  R G Ziegler; S C Rossi; T R Fears; H L Bradlow; H Adlercreutz; D Sepkovic; P Kiuru; K Wahala; J B Vaught; J L Donaldson; R T Falk; C M Fillmore; P K Siiteri; R N Hoover; M H Gail
Journal:  Environ Health Perspect       Date:  1997-04       Impact factor: 9.031

8.  Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.

Authors:  J Geisler; N King; M Dowsett; L Ottestad; S Lundgren; P Walton; P O Kormeset; P E Lønning
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

9.  Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.

Authors:  D C Johannessen; H Adlercreutz; T Fotsis; P E Lønning
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.